Biophytis Reports 2025 Financial Outcomes and Strategic Plans

Biophytis SA has announced its provisional, unaudited financial results for 2025, alongside updates on strategic initiatives. The company noted a transformative year marked by a strategic joint venture in Hong Kong for the Phase 3 trial of BIO101 in sarcopenia. This collaboration is supported by a US$20 million investment commitment from Asian partners. Biophytis also advanced its regulatory and clinical strategies, notably receiving EMA approvals for its SARA and OBA programs.

Despite a decrease in net research expenses, Biophytis still reported a net loss of €7.8 million for 2025, an improvement from the previous year's €9.4 million. However, the company's cash reserves are insufficient to sustain operations beyond September 2026. Efforts to fortify its financial structure include equity fundraising and a recent bond facility enhancement. Trading on Euronext Growth Paris remains paused pending audited financial disclosures due in July 2026.